TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24661576

Group type: EXPERIMENTAL
Intervention: Xylo-oligosaccharides (XOS) 8 g/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis Bi-07 109 CFU/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Xylo-oligosaccharides (XOS) 8 g/d and Bifidobacterium animalis subsp. lactis Bi-07 109 CFU/d
Number of subjects: 0
Study: 22222473

Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.5-3.5 vol.%) and Remifentanil (0-12 ng/ml)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fixed C50(O) Hierarchical model
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Minto model
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Greco model
Number of subjects: 40
Study: 20500891

Group type: EXPERIMENTAL
Intervention: Education programme delivered to GPs and care staff in the intervention groups.
Number of subjects: 351

Group type: COMPARATOR
Intervention: Control group (no education intervention).
Number of subjects: 351
Study: 18062108

Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 25

Group type: COMPARATOR
Intervention: Modified Widman flap surgery
Number of subjects: 25
Study: 15861196

Group type: EXPERIMENTAL
Intervention: Polyurethane bags
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no polyurethane bags)
Number of subjects: 0
Study: 12370798

Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin 200 IU daily for 3 months
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 260
Study: 10213650

Group type: EXPERIMENTAL
Intervention: Midodrine (10 mg oral dose pre-HD)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cool dialysate (35.5 degrees C)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Combination therapy (midodrine 10 mg and dialysate temperature 35.5 degrees C)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control phase (no treatment)
Number of subjects: 11
Study: 7788948

Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 1973547

Group type: EXPERIMENTAL
Intervention: Remoxipride
Number of subjects: 71

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 71
Study: 6111161

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (0.8 mg p. o.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beta-receptor-blocker (Mepindolol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of beta-receptor-blocker (Oxprenolol) and calcium-antagonist (Fendiline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 0
Study: 31324842

Group type: EXPERIMENTAL
Intervention: Caffeine and carbohydrate (CHO + CAFF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carbohydrate only (CHO)
Number of subjects: 0
Study: 28280975

Group type: EXPERIMENTAL
Intervention: Nordic hamstring (NH) eccentric strength training combined with static stretching for 6 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Static stretching
Number of subjects: 20
Study: 25994567

Group type: EXPERIMENTAL
Intervention: n-3 PUFA therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: corn oil therapy (control)
Number of subjects: 60
Study: 22854015

Group type: EXPERIMENTAL
Intervention: Guided Disclosure Protocol (writing about stressful life experiences)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Writing about positive life experiences
Number of subjects: 122

Group type: COMPARATOR
Intervention: Writing about plans for the day
Number of subjects: 122
Study: 19681930

Group type: EXPERIMENTAL
Intervention: BoneCeramic®
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (naturally healed sockets)
Number of subjects: 10
Study: 19131417

Group type: EXPERIMENTAL
Intervention: Test characteristics (sensitivity and specificity)
Number of subjects: 1502

Group type: EXPERIMENTAL
Intervention: Intended clinical management (discontinue erythromycin or discharge)
Number of subjects: 1502

Group type: EXPERIMENTAL
Intervention: Intended clinical management (hospitalisation)
Number of subjects: 1502
Study: 17381356

Group type: EXPERIMENTAL
Intervention: Percutaneous laser ablation (PLA)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Levothyroxine therapy (LT4)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Follow-up
Number of subjects: 62
Study: 16935904

Group type: EXPERIMENTAL
Intervention: Darbepoetin-alpha
Number of subjects: 13

Group type: COMPARATOR
Intervention: Epoetin-beta
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Darbepoetin-alpha and Epoetin-beta
Number of subjects: 13
Study: 12749490

Group type: EXPERIMENTAL
Intervention: Permethrin-treated bed nets (ITNs)
Number of subjects: 644

Group type: COMPARATOR
Intervention: Control group (no ITNs)
Number of subjects: 644
Study: 10487974

Group type: EXPERIMENTAL
Intervention: Antioxidant (Vitamin E)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8712656

Group type: EXPERIMENTAL
Intervention: Nasal packing for 2 hours
Number of subjects: 72

Group type: COMPARATOR
Intervention: Nasal packing for 24 hours
Number of subjects: 72
Study: 1928883

Group type: EXPERIMENTAL
Intervention: Hyperbaric treatment (simulated descent of 1,432 m (4,600 ft) in a hyperbaric chamber pressurized to 120 mm Hg (2.3 PSI) above ambient pressure)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oxygen treatment (4 L of oxygen given by facemask)
Number of subjects: 24
Study: 6761082

Group type: EXPERIMENTAL
Intervention: Ornidazole (500 mg every 12 h i.v. or orally)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Clindamycin (600 mg every 8 h i.v.)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Ornidazole
Number of subjects: 140

Group type: COMPARATOR
Intervention: Clindamycin
Number of subjects: 140
Study: 31289059

Group type: EXPERIMENTAL
Intervention: Acupuncture as an adjunctive therapy to routine medical care
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine pain management without acupuncture
Number of subjects: 30
Study: 28492439

Group type: EXPERIMENTAL
Intervention: Retrobulbar block with 0.5% ropivacaine (n = 13)
Number of subjects: 28

Group type: COMPARATOR
Intervention: General anesthesia plus normal saline (n = 15)
Number of subjects: 28
Study: 25195191

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gaboxadol 15 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiagabine 15 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23234802

Group type: EXPERIMENTAL
Intervention: Inhaled mannitol (400 mg)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control (mannitol 50 mg)
Number of subjects: 600
Study: 21241954

Group type: EXPERIMENTAL
Intervention: CLON‐XR 0.2 mg/day
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: CLON‐XR 0.4 mg/day
Number of subjects: 236

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study: 19229716

Group type: EXPERIMENTAL
Intervention: Group music intervention (50 minutes, 3 times per week for 5 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 20
Study: 16837877

Group type: EXPERIMENTAL
Intervention: Continued exercise participation after a 6-week walking program
Number of subjects: 23

Group type: COMPARATOR
Intervention: 6-week walking program at 50% heart rate reserve
Number of subjects: 23
Study: 15097154

Group type: EXPERIMENTAL
Intervention: TPV 1200 mg twice daily
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: TPV/r 300/200 mg twice daily
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: TPV/r 1200/200 mg twice daily
Number of subjects: 31

Group type: COMPARATOR
Intervention: TPV 1200 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: TPV/r 300/200 mg
Number of subjects: 31
Study: 11069312

Group type: EXPERIMENTAL
Intervention: Budesonide for inducing remission in active Crohn's disease
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Budesonide for reducing corticosteroid-related adverse events
Number of subjects: 12

Group type: COMPARATOR
Intervention: Budesonide for preventing relapse in medically induced remission
Number of subjects: 12

Group type: COMPARATOR
Intervention: Budesonide for preventing endoscopic recurrence in surgically induced remission
Number of subjects: 12

Group type: COMPARATOR
Intervention: Budesonide in long-term treatment for corticosteroid-related adverse effects
Number of subjects: 12
Study: 9262887

Group type: EXPERIMENTAL
Intervention: Serial sevens test
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Serial threes test
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Recitation of months of year in reverse order (MOYR)
Number of subjects: 631

Group type: COMPARATOR
Intervention: Overall performance
Number of subjects: 631
Study: 8261475

Group type: EXPERIMENTAL
Intervention: Intravenous heparin following tissue plasminogen activator (t-PA) administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thrombolytic therapy with t-PA
Number of subjects: 0
Study: 2858456

Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Prochlorperazine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 28521063

Group type: EXPERIMENTAL
Intervention: Disclosure messages about toxic products and health effects associated with cigarette constituents
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Disclosure messages including carcinogenic health effects
Number of subjects: 388
Study: 25172877

Group type: EXPERIMENTAL
Intervention: Automated insulin pump system
Number of subjects: 35

Group type: COMPARATOR
Intervention: Manual BG entry system
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Automated insulin pump system in adolescents with suboptimal baseline BG frequency
Number of subjects: 35
Study: 23613806

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 grams daily
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 4 grams daily divided BID
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (both dosages)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 66
Study: 21043366

Group type: EXPERIMENTAL
Intervention: SCE-B 0.3-mg tablets
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SCE-B 1.25-mg tablets
Number of subjects: 28
Study: 18035495

Group type: EXPERIMENTAL
Intervention: 24-h recall rating of average post-operative pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peak pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: End pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peak and end pain together
Number of subjects: 0
Study: 16793845

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 14687523

Group type: EXPERIMENTAL
Intervention: Bing Shi Yu Shang ointment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Jing Wan Hong ointment
Number of subjects: 200
Study: 12705106

Group type: EXPERIMENTAL
Intervention: Distraction training
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control
Number of subjects: 64
Study: 10481524

Group type: EXPERIMENTAL
Intervention: Nocturnal NIPPV and continued LTOT (Group II)
Number of subjects: 19

Group type: COMPARATOR
Intervention: LTOT only (Group I)
Number of subjects: 19
Study: 8942501

Group type: EXPERIMENTAL
Intervention: Home uterine activity monitoring (monitored group)
Number of subjects: 339

Group type: COMPARATOR
Intervention: High-risk prenatal care alone (not monitored group)
Number of subjects: 339
Study: 1773368

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study: 6762247

Group type: EXPERIMENTAL
Intervention: Intrapleural BCG plus oral isoniazid (INH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intrapleural saline plus oral placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial white count and neutrophil count elevations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low 29 degrees C T cell rosette index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serial immunological tests
Number of subjects: 0
Study: 30696573

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (500 mg daily from enrolment prepregnancy until 20 weeks' gestation)
Number of subjects: 1355

Group type: COMPARATOR
Intervention: Placebo (500 mg daily from enrolment prepregnancy until 20 weeks' gestation)
Number of subjects: 1355

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (500 mg daily) with compliance >80%
Number of subjects: 1355

Group type: COMPARATOR
Intervention: Placebo (500 mg daily) with compliance >80%
Number of subjects: 1355
Study: 27435048

Group type: EXPERIMENTAL
Intervention: Alternating chemoradiotherapy (ACRT) consisting of two cycles of chemotherapy (5‐fluorouracil and cisplatin) and radiotherapy; administered alternately over weeks 1-7
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Alternating chemoradiotherapy (ACRT)
Number of subjects: 28
Study: 27022822

Group type: EXPERIMENTAL
Intervention: Continued thienopyridine plus aspirin (18 months)
Number of subjects: 19684

Group type: COMPARATOR
Intervention: Placebo plus aspirin (18 months)
Number of subjects: 19684
Study: 25141111

Group type: EXPERIMENTAL
Intervention: Controlled medial branch block
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sham blockade (saline injection)
Number of subjects: 54
Study: 22607852

Group type: EXPERIMENTAL
Intervention: Treatment decisions guided by central BP estimated using radial tonometry
Number of subjects: 284

Group type: COMPARATOR
Intervention: Usual care based on office, home, and 24‐hour ambulatory brachial BP
Number of subjects: 284
Study: 19411100

Group type: EXPERIMENTAL
Intervention: Oral rivaroxaban 10 mg once daily
Number of subjects: 3148

Group type: COMPARATOR
Intervention: Subcutaneous enoxaparin 30 mg every 12 h
Number of subjects: 3148
Study: 17548111

Group type: EXPERIMENTAL
Intervention: Massage therapy (three 15‐min massages each day for 5 consecutive days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 16340050

Group type: EXPERIMENTAL
Intervention: Oil massage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Massage without oil
Number of subjects: 0

Group type: COMPARATOR
Intervention: No massage
Number of subjects: 0
Study: 12473805

Group type: EXPERIMENTAL
Intervention: Valaciclovir 500 mg twice daily for 3 days
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Valaciclovir 500 mg twice daily for 5 days
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Valaciclovir treatment initiated within 6 hours of first sign or symptom
Number of subjects: 531
Study: 10075224

Group type: EXPERIMENTAL
Intervention: Medical abortion (600 mg of mifepristone followed by 400 microg of misoprostol after 48 h)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Surgical abortion
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Medical abortion (adolescents)
Number of subjects: 500
Study: 7926971

Group type: EXPERIMENTAL
Intervention: G-CSF (5 micrograms/kg subcutaneously)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: GM-CSF (10 micrograms/kg in a 6-h IV infusion)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (no growth factors)
Number of subjects: 23
Study: 2508502

Group type: EXPERIMENTAL
Intervention: Metrifonate (MT, 10 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Praziquantel (PR, 40 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 0
Study: 775883

Group type: EXPERIMENTAL
Intervention: Haloperidol (0.025 mg/kg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Haloperidol (0.05 mg/kg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.3 mg/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31034316

Group type: EXPERIMENTAL
Intervention: Protonics™ knee brace
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sport cord
Number of subjects: 41
Study: 29389471

Group type: EXPERIMENTAL
Intervention: Abdominal massage (15-min, twice a day for three days)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Routine cares
Number of subjects: 70
Study: 26398685

Group type: EXPERIMENTAL
Intervention: 175 μg of intravitreal ocriplasmin injection
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 25767804

Group type: EXPERIMENTAL
Intervention: Preoperative virtual design and assisted operation (virtual group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Direct open reduction and internal fixation (control group)
Number of subjects: 32
Study: 22417767

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 21
Study: 19948945

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg) with diphenhydramine (CYP2D6 inhibitor)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Diphenhydramine (CYP2D6 inhibitor)
Number of subjects: 36
Study: 18544981

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant hormonal therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiation with hormones
Number of subjects: 0
Study: 16340187

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg by rectiole, followed by 10 mg tablets twice daily for 3 days
Number of subjects: 880

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 880
Study: 14596675

Group type: EXPERIMENTAL
Intervention: Essential amino acids (AA)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Iso-caloric control
Number of subjects: 28

Group type: COMPARATOR
Intervention: Fasting control
Number of subjects: 28
Study: 11757637

Group type: EXPERIMENTAL
Intervention: Low-dose spiral computed tomography (CT) scan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lung cancer screening
Number of subjects: 0
Study: 9326185

Group type: EXPERIMENTAL
Intervention: Patients informed about the real nature of the cap of the pill bottle
Number of subjects: 68

Group type: COMPARATOR
Intervention: Patients not informed about the real nature of the cap of the pill bottle
Number of subjects: 68
Study: 8330924

Group type: EXPERIMENTAL
Intervention: Tinospora cordifolia (16 mg/kg/day orally)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional management (vitamin K, antibiotics, biliary drainage)
Number of subjects: 30
Study: 3524221

Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 106

Group type: COMPARATOR
Intervention: Amikacin
Number of subjects: 106
Study: 2504673

Group type: EXPERIMENTAL
Intervention: Isosorbide 20 mg twice a day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sustained released isosorbide 40 mg once daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg twice a day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31525422

Group type: EXPERIMENTAL
Intervention: Electrospun nanoscale P(LLA-CL)/fibrinogen patch
Number of subjects: 172

Group type: COMPARATOR
Intervention: Porcine small intestine submucosa patch
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 172
Study: 27138609

Group type: EXPERIMENTAL
Intervention: Minimal invasive intramedullary fixation with Sonoma Crx device
Number of subjects: 75

Group type: COMPARATOR
Intervention: 3.5 mm locking compression plate (LCP)
Number of subjects: 75
Study: 26003584

Group type: EXPERIMENTAL
Intervention: Workplace intervention aimed at promoting employees' schedule control and supervisor support for personal and family life.
Number of subjects: 93

Group type: COMPARATOR
Intervention: Comparison group (no intervention).
Number of subjects: 93
Study: 23554858

Group type: EXPERIMENTAL
Intervention: Cold temperature (1°C decrease in air temperature)
Number of subjects: 16254

Group type: EXPERIMENTAL
Intervention: Cold temperature (5°C decrease in mean temperature)
Number of subjects: 16254

Group type: EXPERIMENTAL
Intervention: Higher barometric pressure, more hours of sunshine, and lower humidity
Number of subjects: 16254
Study: 22014673

Group type: EXPERIMENTAL
Intervention: Healthy Lifestyles for People with Disabilities health promotion program
Number of subjects: 95
Study: 19211938

Group type: EXPERIMENTAL
Intervention: High-dose imatinib (400 mg twice daily)
Number of subjects: 78
Study: 17092520

Group type: EXPERIMENTAL
Intervention: Arundic acid (AA) daily infusion for 7 days
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo daily infusion for 7 days
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Arundic acid (AA)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both AA and placebo
Number of subjects: 86
Study: 12848402

Group type: EXPERIMENTAL
Intervention: Health Visiting support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-exclusion from Health Visiting support
Number of subjects: 0
Study: 14564617

Group type: EXPERIMENTAL
Intervention: Early oral feeding (EOF)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Nil per os (NPO)
Number of subjects: 31
Study: 8906519

Group type: EXPERIMENTAL
Intervention: 25 mg cilazapril
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 1844105

Group type: EXPERIMENTAL
Intervention: Cefotiam (2 g with anesthetic induction)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Cefazolin (continued administration for 48 hours)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Cefotiam
Number of subjects: 207

Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 207
Study: 6127946

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31628428

Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg once daily continuously
Number of subjects: 269

Group type: COMPARATOR
Intervention: Chlorambucil 0.5-0.8 mg/kg for ≤12 cycles
Number of subjects: 269
Study: 31495668

Group type: EXPERIMENTAL
Intervention: Dual-task walking (DTW)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Single-task treadmill walking (TMW)
Number of subjects: 22